AI Article Synopsis
- The study investigates the effects of Pimobendan on dogs with asymptomatic degenerative mitral valve disease (DMVD) without cardiomegaly, using exercise testing and cardiac biomarker measurements.
- Dogs receiving Pimobendan showed significantly lower NT-proBNP levels after exercise compared to the placebo group, suggesting a reduction in cardiac stress.
- The findings indicate that Pimobendan may contribute to improved cardiac health in dogs with early-stage DMVD, potentially leading to longer survival rates.
Article Abstract
Background: Exercise testing in conjunction with measurement of cardiac biomarkers NT-proBNP and cTnI is a useful tool for monitoring the effect of treatment on cardiac patients. Administering Pimobendan in dogs with degenerative mitral valve disease (DMVD) and cardiomegaly results in delaying the onset of clinical symptoms and prolonging life. Its effect in dogs with DMVD without cardiomegaly has not been well examined. The aim of the current study was to investigate the effect of administering Pimobendan in dogs with DMVD without cardiomegaly using exercise testing in conjunction with measuring cardiac biomarkers in addition to echocardiography. Twenty-one dogs with asymptomatic DMVD without echocardiographic signs of cardiomegaly participated in a randomised, double-blinded trial. Dogs were divided into a Pimobendan-group (n = 11) and a placebo-group (n = 10) in a double-blinded study design and underwent a standardised submaximal exercise test (SSET). One dog in the Pimobendan-group was retrospectively removed from the study after being diagnosed with Leishmaniosis. Cardiac biomarkers NT-proBNP and cTnI were measured before and after exercise. Follow-up appointments were performed at days 90 and 180.
Results: Dogs in the Pimobendan-group had significantly lower post-exercise NT-proBNP-levels after being administered Pimobendan than at the beginning of the study. They also had lower pre- and post-exercise-NT-proBNP-levels than those dogs in the placebo-group. There was neither a significant difference regarding the measured cTnI levels nor an increase in cTnI between the groups at any time.
Conclusions: Pimobendan lowers NT-proBNP in dogs with presymptomatic mitral valve disease without cardiomegaly before and after submaximal exercise. This indicates a reduction in cardiac wall stress. If dogs with asymptomatic DMVD without cardiomegaly benefit from treatment with Pimobendan (for example, through a longer survival time) warrants further investigation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617668 | PMC |
| http://dx.doi.org/10.1186/s12917-019-1980-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Effect of a specially formulated diet on progression of heart enlargement in dogs with subclinical degenerative mitral valve disease.
J Vet Intern Med
November 2023
Nestlé Purina Research, St. Louis, Missouri, USA.
Background: Previous studies in dogs with degenerative mitral valve disease (DMVD) have identified altered myocardial energy metabolism and oxidation, which might contribute to cardiac hypertrophy. Diets rich in medium chain fatty acids and antioxidants are a potential means of treatment. A previous clinical study found significantly smaller left atrial diameter (LAD) and left atrium-to-aorta diameter ratio (LA : Ao) in dogs with subclinical DMVD fed a specially formulated diet vs control diet for 6 months.
View Article and Find Full Text PDFThe effect of treatment with pimobendan in dogs with preclinical mitral valve disease - a placebo-controlled double-blinded crossover study.
BMC Vet Res
September 2021
Clinic for Small Animals, University of Veterinary Medicine Hannover, Hannover, Germany.
Article Synopsis
- Pimobendan is a medicine used for dogs with heart problems, specifically congestive heart failure and a condition called degenerative mitral valve disease.
- A study with 15 dogs tested how effective Pimobendan is by comparing it to a placebo (a fake treatment) over six months.
- Results showed that dogs taking Pimobendan were more active, their heart size improved, and their heart-related test results got better compared to when they took the placebo.
Accuracy of history, physical examination, cardiac biomarkers, and biochemical variables in identifying dogs with stage B2 degenerative mitral valve disease.
J Vet Intern Med
March 2021
Department of Clinical Science and Services, Royal Veterinary College, University of London, London, UK.
Background: Treatment is indicated in dogs with preclinical degenerative mitral valve disease (DMVD) and cardiomegaly (stage B2). This is best diagnosed using echocardiography; however, relying upon this limits access to accurate diagnosis.
Objectives: To evaluate whether cardiac biomarker concentrations can be used alongside other clinical data to identify stage B2 dogs.
Effect of Pimobendan on NT-proBNP and c troponin I before and after a submaximal exercise test in dogs with preclinical mitral valve disease without cardiomegaly - a randomised, double-blinded trial.
BMC Vet Res
July 2019
Small Animal Clinic, University of Veterinary Medicine Hanover, Foundation, Bünteweg 9, D-30559, Hannover, Germany.
Article Synopsis
- The study investigates the effects of Pimobendan on dogs with asymptomatic degenerative mitral valve disease (DMVD) without cardiomegaly, using exercise testing and cardiac biomarker measurements.
- Dogs receiving Pimobendan showed significantly lower NT-proBNP levels after exercise compared to the placebo group, suggesting a reduction in cardiac stress.
- The findings indicate that Pimobendan may contribute to improved cardiac health in dogs with early-stage DMVD, potentially leading to longer survival rates.
Association between atrial fibrillation and right-sided manifestations of congestive heart failure in dogs with degenerative mitral valve disease or dilated cardiomyopathy.
J Vet Cardiol
February 2019
Department of Veterinary Pathology, College of Veterinary Medicine, Iowa State University, 1809 S. Riverside Drive, Ames, IA 50011, USA.
Introduction: To determine whether dogs with atrial fibrillation (AF) are more likely to develop right-sided manifestations of congestive heart failure (R-CHF) than dogs without AF.
Animals: Two hundred twenty dogs diagnosed with congestive heart failure (CHF) secondary to degenerative mitral valve disease (DMVD, n = 155) or dilated cardiomyopathy (DCM, n = 65) at a referral institution.
Methods: Medical records were reviewed to extract relevant clinical and echocardiographic data.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!